IgA nephropathy

IgA nephropathy (IgAN) – also known as Berger’s disease – is the most common form of glomerulonephritis, a chronic inflammatory condition of the kidney, in the Western world. Today, there are no approved treatments for IgAN.


Nefecon is a potential treatment for patients with IgA nephropathy (IgAN) at risk of developing end-stage renal disease (ESRD), and has received orphan drug designation in IgAN by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Orphan drugs

Orphan drug designation was introduced by regulatory authorities worldwide as a way of encouraging research and development of therapies for patients affected by orphan diseases with unmet medical needs.